Budget impact analysis of breast cancer medications: a systematic review

References

• Ma X, Yu H. Cancer issue: Global Burden of Cancer. Yale J Biol Med [Internet].2006;79(3–4):85.
   PubMedGoogle Scholar
• Sharma R. Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018. Breast Cancer Res Treat. 2021;187(2):557–567. https://doi.org/10.1007/s10549-020-06083-6.
   PubMed Web of Science ®Google Scholar
• Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat [Internet]. 2019;173(1):37–48. https://doi.org/10.1007/s10549-018-4921-9.
   PubMed Web of Science ®Google Scholar
• Chen Z, Xu L, Shi W, Zeng F, Zhuo R, Hao X, et al. Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017. Breast Cancer Res Treat [Internet]. 2020;180(2):481–490. https://doi.org/10.1007/s10549-020-05561-1.
   PubMed Web of Science ®Google Scholar
• Faria EH, Kim D, Sisconetto RM, Cucio VFM, dos Reis Ferreira PP, Alves BSR, et al. Analysis of knowledge about male breast cancer among higher education male students. Eur J Breast Heal [Internet]. 2021;17(4):333.
   PubMed Web of Science ®Google Scholar
• Guo F, Kuo YF, Shih YCT, Giordano SH, Berenson AB. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer [Internet]. 2018;124(17):3500–3509. https://doi.org/10.1002/cncr.31638.
   PubMed Web of Science ®Google Scholar
• Al-Zalabani AH, Alharbi KD, Fallatah NI, Alqabshawi RI, Al-Zalabani AA, Alghamdi SM. Breast cancer knowledge and screening practice and barriers among women in Madinah, Saudi Arabia. J Cancer Educ [Internet]. 2018;33(1):201–207. https://doi.org/10.1007/s13187-016-1057-7.
   Web of Science ®Google Scholar
• Rogoz B, Houzé de I’Aulnoit A, Duhamel A, Houzé de I’Aulnoit D. Thirty-year trends of survival and time-varying effects of prognostic factors in patients with metastatic breast cancer—a single institution experience. Clin Breast Cancer. 2018;18(3):246–253.
   PubMed Web of Science ®Google Scholar
• Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, et al. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr [Internet]. 2018;2(4).
   Google Scholar
• Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011;9(1):16–32.
   PubMed Web of Science ®Google Scholar
• Mitri Z, Constantine T, O’regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012.
   Google Scholar
• Lorusso G, Rüegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol. 2012;22(3):226–233.
   PubMed Web of Science ®Google Scholar
• Zou Y, Zou X, Zheng S, Tang H, Zhang L, Liu P, et al. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis. Ther Adv Med Oncol [Internet]. 2020;12:1758835920940928.
   Web of Science ®Google Scholar
• Schettini F, Giuliano M, Giudici F, Conte B, De Placido P, Venturini S, et al. Endocrine-based treatments in clinically-relevant subgroups of hormone receptor-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis. Cancers. 2021;13(6):1458.
   PubMed Web of Science ®Google Scholar
• Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: biology, biomarkers, and treatments. Int Immunopharmacol. 2020;1(84): 106535.
   Google Scholar
• Roberto M, Astone A, Botticelli A, Carbognin L, Cassano A, D’auria G, et al. CDK4/6 inhibitor treatments in patients with hormone receptor positive, Her2 negative advanced breast cancer: potential molecular mechanisms, clinical implications and future perspectives. Cancers. 2021;13(2):332.
   PubMed Web of Science ®Google Scholar
• Berghuis AMS, Koffijberg H, Terstappen LWMM, Sleijfer S, IJzerman MJ. Evidence on the cost of breast cancer drugs is required for rational decision making. Ecancermedicalscience. 2018;12:825.
   PubMed Web of Science ®Google Scholar
• Budget impact analysis guidelines developed in France. Pharmaco-Economics Outcomes News. 2018;794(1):9–9. https://doi.org/10.1007/s40274-018-4607-x.
   Google Scholar
• Chugh Y, De Francesco M, Prinja S. Systematic literature review of guidelines on budget impact analysis for health technology assessment. Appl Heal Econ Heal Policy. 2021;19(6):825–838. https://doi.org/10.1007/s40258-021-00652-6.
   PubMed Web of Science ®Google Scholar
• Foroutan N, Tarride JE, Xie F, Levine M. A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions. Clin Outcomes Res CEOR [Internet]. 2018;10:821.
   PubMed Web of Science ®Google Scholar
• Finkelstein EA, Krishnan A, Doble B. Beyond cost-effectiveness: a five-step framework for appraising the value of health technologies in Asia-Pacific. Int J Health Plann Manage [Internet]. 2020;35(1):397–408. https://doi.org/10.1002/hpm.2851.
   PubMed Web of Science ®Google Scholar
• Carvalho N, Jit M, Cox S, Yoong J, Hutubessy RCW. Capturing budget impact considerations within economic evaluations: a systematic review of economic evaluations of rotavirus vaccine in low- and middle-income countries and a proposed assessment framework. Pharmacoeconomics [Internet]. 2018;36(1):79–90. https://doi.org/10.1007/s40273-017-0569-2.
   PubMed Web of Science ®Google Scholar
• Kazi DS, Virani SS. Implications of cost-effectiveness analyses of lipid-lowering therapies: from the policy-maker’s desk to the patient’s bedside. Prog Cardiovasc Dis. 2019;62(5):406–413.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, Caro JJ, Lee KM, Minchin M, et al. Budget impact analysis principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. VALUE Heal. 2014;17(1):5–14.
   PubMed Web of Science ®Google Scholar
• Han L, Zhang X, Fu WQ, Sun CY, Zhao XM, Zhou LR, et al. A systematic review of the budget impact analyses for antitumor drugs of lung cancer. Cost Eff Resour Alloc [Internet]. 2020;18(1).
   PubMed Web of Science ®Google Scholar
• Cesarec A, Likić R. Budget impact analysis of biosimilar trastuzumab for the treatment of breast cancer in Croatia. Appl Health Econ Health Policy. 2017;15(2):277–286.
   PubMed Web of Science ®Google Scholar
• Pouwels XGLV, Ramaekers BLT, Geurts SME, Erdkamp F, Vriens BEPJ, Aaldering KNA, et al. An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry. Acta Oncol. 2020;59(9):1123–1130.
   PubMed Web of Science ®Google Scholar
• Lee S-M, Jung J-H, Suh D, Jung Y-S, Yoo S-L, Kim D-W, et al. Budget impact of switching to biosimilar trastuzumab (CT-P6) for the treatment of breast cancer and gastric cancer in 28 European Countries. BioDrugs. 2019;33(4):423–436.
   PubMed Web of Science ®Google Scholar
• Marchetti M, Caruggi M, Colombo G. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. Clin Ther. 2004;26(9):1546–1561.
   PubMed Web of Science ®Google Scholar
• Benjamin L, Buthion V, Iskedjian M, Farah B, Rioufol C, Vidal-Trécan G. Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer. J Med Econ. 2013;16(1):96–107.
   PubMedGoogle Scholar
• Purmonen TT, Auvinen PK, Martikainen JA. Budget impact analysis of trastuzumab in early breast cancer: a hospital district perspective. Int J Technol Assess Health Care. 2010;26(2):163–169.
   PubMed Web of Science ®Google Scholar
• Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy. 2008;87(2):146–159.
   PubMed Web of Science ®Google Scholar
• Clarke CS, Hunter RM, Shemilt I, Serra-Sastre V. Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PLoS ONE. 2017;12(3): e0172731.
   Web of Science ®Google Scholar
• Mistry R, Suri G, Young K, Hettle R, May JR, Brixner D, et al. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Curr Med Res Opin. 2018;34(12):2143–2150.
   PubMed Web of Science ®Google Scholar
• Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M. Budget impact analysis of everolimus for estrogen receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients in the United States. Cancer Res. 2012;72 MA-P.
   Google Scholar
• Ho J, Zhang L, Todorova L, Whillans F, Corey-Lisle P, Yuan Y. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer. J Manag Care Pharm. 2009;15(6):467–475.
   PubMed Web of Science ®Google Scholar
• Elsamany S, Elsisi GH, Hassanin F, Jafal M. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):511–518.
   PubMed Web of Science ®Google Scholar
• Genuino AJ, Chaikledkaew U, Guerrero AM, Reungwetwattana T, Thakkinstian A. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines. BMC Health Serv Res. 2019;19(1):874.
   PubMed Web of Science ®Google Scholar
• Lewis L, Taylor M, Suriya Ertugyrovna Y, Kuanysh Shadybayevich N, Kaldygul Kabakovna S, Ramil ZA. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. J Med Econ. 2015;18(3):189–199.
   PubMed Web of Science ®Google Scholar
• Ivanov DA, Dyakov IN, Zyryanov SК. Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price. Farmakoekonomika [Internet]. 2021;14(2):103–114.
   Google Scholar
• Avxentyev NA, Lubennikova EV, Frolov MY. Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer. Farmakoekonomika [Internet]. 2019;12(4):279–290.
   Google Scholar
• Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomics. 2007;25(5):429–442.
   PubMed Web of Science ®Google Scholar
• Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ. 2013;16(2):278–288.
   PubMedGoogle Scholar
• Hiqa. Guidelines for the Budget Impact Analysis of Health Technologies in Ireland Health Information and Quality Authority.
   Google Scholar
• Ghabri S, Autin E, Poullié AI, Josselin JM. The French National Authority for Health (HAS) Guidelines for conducting budget impact analyses (BIA). Pharmacoeconomics [Internet]. 2018;36(4):407–417.
   PubMed Web of Science ®Google Scholar
• Prinja S, Chugh Y, Rajsekar K, Muraleedharan VR. National methodological guidelines to conduct budget impact analysis for health technology assessment in India. Appl Health Econ Health Policy [Internet]. 2021;19(6):811–823. https://doi.org/10.1007/s40258-021-00668-y.
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Sullivan SD, Annemans L, Caro J, Daniel Mullins C, Nuijten M, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices-budget impact analysis. 2007;1098.
   Google Scholar
• Marshall DA, Douglas PR, Drummond MF, Torrance GW, MacLeod S, Manti O, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics [Internet]. 2008;26(6):477–495.
   PubMed Web of Science ®Google Scholar
• Luo Z, Ruan Z, Yao D, Ung COL, Lai Y, Hu H. Budget impact analysis of diabetes drugs: a systematic literature review. Front Public Heal [Internet]. 2021;9:765999.
   PubMed Web of Science ®Google Scholar
• Han L, Zhang X, Fu WQ, Sun CY, Zhao XM, Zhou LR, et al. A systematic review of the budget impact analyses for antitumor drugs of lung cancer. Cost Eff Resour Alloc [Internet]. 2020;18(1):1–10. https://doi.org/10.1186/s12962-020-00253-5.
   PubMed Web of Science ®Google Scholar
• Grégoire G, Derderian F, Le Lorier J. Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias?J Clin Epidemiol [Internet]. 1995;48(1):159–163.
   PubMed Web of Science ®Google Scholar